Future research should also include clinical evaluations of C-PAC in patients with GERD or BE, particularly those with mutant or aberrant TP53 or at increased risk for EAC progression based on modeling or the presence of additional risk factors. This evidence concerns the gene TP53 and Barrett esophagus.